Tag Archives: Approves

FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine

[unable to retrieve full-text content]NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.1 Qulipta is the first… Drugs.com – New Drug Approvals

U.S. FDA Approves Kite’s Tecartus as the First and Only CAR-T for Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

[unable to retrieve full-text content]SANTA MONICA, Calif.–(BUSINESS WIRE) October 01, 2021 — Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has granted approval for Tecartus® (brexucabtagene autoleucel) for the treatment of… Drugs.com – New Drug Approvals

FDA Approves Livmarli (maralixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

[unable to retrieve full-text content]FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 29, 2021– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Livmarli (maralixibat) oral solution for… Drugs.com – New Drug Approvals

FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity

FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ — Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss medication with once-weekly dosing. Wegovy™ is used with a reduced calorie meal plan and… Read More »